{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,19]],"date-time":"2026-05-19T05:07:10Z","timestamp":1779167230113,"version":"3.51.4"},"reference-count":24,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100004281","name":"Narodowe Centrum Nauki","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004281","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biochemical and Biophysical Research Communications"],"published-print":{"date-parts":[[2026,7]]},"DOI":"10.1016\/j.bbrc.2026.153898","type":"journal-article","created":{"date-parts":[[2026,5,5]],"date-time":"2026-05-05T00:51:52Z","timestamp":1777942312000},"page":"153898","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"C","title":["Specific impact of acridine antitumor agents on the survival potency of selected non-cancerous cells: Toxicological insights"],"prefix":"10.1016","volume":"821","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5914-1591","authenticated-orcid":false,"given":"Monika","family":"Paw\u0142owska","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jacek","family":"Grebowski","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0003-2278-6913","authenticated-orcid":false,"given":"Weronika","family":"Misztal","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8544-5778","authenticated-orcid":false,"given":"Aneta","family":"Balcerczyk","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1008-0548","authenticated-orcid":false,"given":"Anita","family":"Krokosz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zofia","family":"Mazerska","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.bbrc.2026.153898_bib1","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2018.00245","article-title":"Editorial: adverse effects of cancer chemotherapy: anything new to improve tolerance and reduce sequelae?","volume":"9","author":"Nurgali","year":"2018","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.bbrc.2026.153898_bib2","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2022.1007762","article-title":"Editorial: cancer therapy: the challenge of handling a double-edged sword","volume":"13","author":"Nurgali","year":"2022","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.bbrc.2026.153898_bib3","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1016\/j.jpainsymman.2017.03.017","article-title":"Cancer treatment side effects: a meta-analysis of the relationship between response expectancies and experience","volume":"54","author":"Devlin","year":"2017","journal-title":"J. Pain Symptom Manag."},{"key":"10.1016\/j.bbrc.2026.153898_bib4","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2020.112599","article-title":"Design, synthesis and high antitumor potential of new unsymmetrical bisacridine derivatives towards human solid tumors, specifically pancreatic cancers and their unique ability to stabilize DNA G-quadruplexes","volume":"204","author":"Paluszkiewicz","year":"2020","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.bbrc.2026.153898_bib5","author":"Kurdyn"},{"key":"10.1016\/j.bbrc.2026.153898_bib6","doi-asserted-by":"crossref","DOI":"10.1016\/j.omtn.2025.102513","article-title":"The interactions of Pu22 G-quadruplex, derived from c-MYC promoter sequence, with antitumor acridine derivatives-An NMR\/MD combined study","volume":"36","author":"Laskowski","year":"2025","journal-title":"Mol. Ther. Nucleic Acids"},{"key":"10.1016\/j.bbrc.2026.153898_bib7","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1016\/j.ejca.2009.12.005","article-title":"Evaluation of the safety of C-1311 (SYMADEX) administered in a phase 1 dose escalation trial as a weekly infusion for 3 consecutive weeks in patients with advanced solid tumours","volume":"46","author":"Isambert","year":"2010","journal-title":"Eur. J. Cancer"},{"key":"10.1016\/j.bbrc.2026.153898_bib8","doi-asserted-by":"crossref","first-page":"31187","DOI":"10.18632\/oncotarget.16102","article-title":"The imidazoacridinone C-1311 induces p53-dependent senescence or p53-independent apoptosis and sensitizes cancer cells to radiation","volume":"8","author":"Skwarska","year":"2017","journal-title":"Oncotarget"},{"key":"10.1016\/j.bbrc.2026.153898_bib9","doi-asserted-by":"crossref","first-page":"1055","DOI":"10.1200\/jco.2008.26.15_suppl.1055","article-title":"Phase II trial of C1311, a novel inhibitor of topoisomerase II in advanced breast cancer","volume":"26","author":"Capizzi","year":"2008","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.bbrc.2026.153898_bib10","doi-asserted-by":"crossref","first-page":"2852","DOI":"10.1021\/jm00172a028","article-title":"8-Substituted 5-[(aminoalkyl)amino]-6H-v-triazolo[4,5,1-de]acridin-6-ones as potential antineoplastic agents. Synthesis and biological activity","volume":"33","author":"Cholody","year":"1990","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.bbrc.2026.153898_bib11","doi-asserted-by":"crossref","first-page":"1035","DOI":"10.1124\/mol.104.000703","article-title":"The antitumor triazoloacridone C-1305 is a topoisomerase II poison with unusual properties","volume":"66","author":"Lemke","year":"2004","journal-title":"Mol. Pharmacol."},{"key":"10.1016\/j.bbrc.2026.153898_bib12","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1016\/0306-3623(94)00143-B","article-title":"Nitracrine and its congeners--an overview","volume":"26","author":"Gniazdowski","year":"1995","journal-title":"Gen. Pharmacol."},{"key":"10.1016\/j.bbrc.2026.153898_bib13","unstructured":"NITRACRINE, (n.d.). https:\/\/gsrs.ncats.nih.gov\/ginas\/app\/ui\/substances\/6760d8e1-a676-48d4-b61f-b8af951d20ac (accessed May 26, 2025)."},{"key":"10.1016\/j.bbrc.2026.153898_bib14","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1097\/01.cad.0000236316.04199.20","article-title":"Preclinical toxicological examination of a putative prostate cancer-specific 4-methyl-1-nitroacridine derivative in rodents","volume":"18","author":"Ashok","year":"2007","journal-title":"Anti Cancer Drugs"},{"key":"10.1016\/j.bbrc.2026.153898_bib15","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1016\/j.cellbi.2005.09.001","article-title":"Interaction of doxorubicin and idarubicin with red blood cells from acute myeloid leukaemia patients","volume":"30","author":"Marczak","year":"2006","journal-title":"Cell Biol. Int."},{"key":"10.1016\/j.bbrc.2026.153898_bib16","first-page":"325","article-title":"The physiologic role of erythrocytes in oxygen delivery and implications for blood storage","volume":"26","author":"Benedik","year":"2014","journal-title":"Crit. Care Nurs. Clin."},{"key":"10.1016\/j.bbrc.2026.153898_bib17","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1016\/j.freeradbiomed.2025.01.052","article-title":"Metallofullerenol Gd@C82(OH)22 preserves human erythrocyte plasma membrane integrity from AAPH-induced oxidative stress: molecular mechanisms and antioxidant activity","volume":"299","author":"Remigante","year":"2025","journal-title":"Free Radic. Biol. Med."},{"key":"10.1016\/j.bbrc.2026.153898_bib18","article-title":"Metallofullerenol Sc3N@C80(OH)18: a new generation radioprotector protecting human erythrocytes against multiple biochemical damage modes upon gamma irradiation, identifying it as a scavenger of Short- and long-lived radicals","author":"Grebowski","year":"2025","journal-title":"Adv. Healthcare Mater."},{"key":"10.1016\/j.bbrc.2026.153898_bib19","doi-asserted-by":"crossref","first-page":"967","DOI":"10.1016\/j.radphyschem.2006.02.004","article-title":"Induction of transient radioresistance in human erythrocytes","volume":"75","author":"Krokosz","year":"2006","journal-title":"Radiat. Phys. Chem."},{"key":"10.1016\/j.bbrc.2026.153898_bib20","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1269\/jrr.45.275","article-title":"The influence of radiation quality on radiation-induced hemolysis and hemoglobin oxidation of human erythrocytes","volume":"45","author":"Puchala","year":"2004","journal-title":"J. Radiat. Res."},{"key":"10.1016\/j.bbrc.2026.153898_bib21","doi-asserted-by":"crossref","first-page":"C720","DOI":"10.1152\/ajpcell.00542.2002","article-title":"Acridine orange induces translocation of phosphatidylserine to red blood cell surface","volume":"285","author":"Koshkaryev","year":"2003","journal-title":"Am. J. Physiol.: Cell Physiol."},{"key":"10.1016\/j.bbrc.2026.153898_bib22","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1080\/15216549700204691","article-title":"The effects of imidazoacridinones, new antineoplastic agents, on the human erythrocyte membrane","volume":"43","author":"J\u00f3zwiak","year":"1997","journal-title":"IUBMB Life"},{"key":"10.1016\/j.bbrc.2026.153898_bib23","doi-asserted-by":"crossref","first-page":"3061","DOI":"10.3390\/ijms23063061","article-title":"c-Myc protein level affected by unsymmetrical bisacridines influences apoptosis and senescence induced in HCT116 colorectal and H460 lung cancer cells","volume":"23","author":"Paw\u0142owska","year":"2022","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.bbrc.2026.153898_bib24","doi-asserted-by":"crossref","first-page":"772","DOI":"10.1016\/S0026-895X(25)09053-4","article-title":"Inhibition of DNA topoisomerase II by imidazoacridinones, new antineoplastic agents with strong activity against solid tumors","volume":"49","author":"Skladanowski","year":"1996","journal-title":"Mol. Pharmacol."}],"container-title":["Biochemical and Biophysical Research Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0006291X26006625?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0006291X26006625?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,19]],"date-time":"2026-05-19T04:12:14Z","timestamp":1779163934000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0006291X26006625"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7]]},"references-count":24,"alternative-id":["S0006291X26006625"],"URL":"https:\/\/doi.org\/10.1016\/j.bbrc.2026.153898","relation":{},"ISSN":["0006-291X"],"issn-type":[{"value":"0006-291X","type":"print"}],"subject":[],"published":{"date-parts":[[2026,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Specific impact of acridine antitumor agents on the survival potency of selected non-cancerous cells: Toxicological insights","name":"articletitle","label":"Article Title"},{"value":"Biochemical and Biophysical Research Communications","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bbrc.2026.153898","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"153898"}}